Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Very low or no dividends
Very poor margins and returns
Slightly negative price performance
Risk / Profitability
Risk: High
Profitability: Modest
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Very low or no dividends
Very poor margins and returns
Slightly negative price performance
$ 7.9
About
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell...
About
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid...
